Financial Highlights (Audited)(HKD Thousand)Year ended31 December20252024Revenue170,011271,372Gross Profit53,382104,720Profit Attributable to Owners of the Company13,68833,440Basic Earnings per Share (HK cents)0.972.37HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - Dynasty Fine Wines Group Limited (“Dynasty” or “the Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its audited annual results for the year ended 31 December 2025 (“the Year”).In 2025, due to the impact of macroeconomy as well as weak demand in wine consumer market in the PRC, the Group’s sales of medium to high-end products significantly declined, resulting in a 37% year-on-year decrease in revenue to HK$170.0 million. In addition, due to the decline in sales revenue and gross margin, as well as an increase in loss allowances for trade receivables owing to extended repayment from certain distributors, the profit attributable to owners of the Company decreased by 59% year-on-year to approximately HK$13.7 million, although such decrease in profit was already partly offset by a net gain on compensatory surrender recognised during the year. Earnings per share of the Company was HK0.97 cents per Share.With strengthened marketing effort for dry white in coastal region and the launch of new white wine and sparkling wine products, sales of white wine products served as the Group’s primary revenue contributor. Sales of red and white wines products accounted for approximately 39% and 54% of the revenue respectively for the year (2024: approximately 41% and 56% respectively). The gross margin of red wine products and white wine products in 2025 were 25% and 35% respectively (2024: 36% and 41% respectively). The overall gross profit margin decreased to 31% in 2025 (2024: 39%), mainly due to change in product mix with more products with lower prices and margin in response to market dynamics and needs during the year.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the year, the Group launched a new gift set product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese-style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. In addition, based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of “tea and wine fusion,” has captured market attention with its unique craftsmanship. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Ningxia Winery won industry praise for their unique flavor and exquisite craftsmanship. In the second half of the year, the Group also introduced new products “Hi” tea-flavoured wine series in response to the market need, which are very suitable for ready-to-drink scenarios among young consumers.In addition to enriching the product matrix, the Group has been closely cooperating with distributors, pressing ahead with its marketing campaign, accelerating the innovation of consumption scenarios, and enhancing and strengthening the wine cultural experience. The Group held its national tour tasting and business events, new products launch ceremonies at various exhibitions and wine fairs, as well as promotion activities for the 20th anniversary of listing in Hong Kong, during which the Group actively promoted its latest product mix that covered all product lines.During the year, two joint venture companies approved by the Group were established in February 2025, for the manufacturing and sales of yellow wine and Chenpi wine and trading of sauce-flavour baijiu products nationwide in the PRC respectively. For the yellow wine project, installation and testing of production equipment of a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu is expected to be completed in the second half of 2026. Upon completion of the project, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry. The project expansion aims to effectively implement Dynasty’s strategic plan, further improving the industrial layout, expanding category tracks, tapping into industry potential, creating new performance growth points, and realising Dynasty Group’s transformation into a full category, full industry-chain enterprise. For the sauce-flavour baijiu segment, Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in the core-market in Tianjin and Shanghai and will be further strategically promoted to other regions in 2026. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales scale of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness.Regarding online sales, the e-commerce team of the Group comprehensively operates online stores itself on the traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based e-commerce platforms, including Rednote, Kuai and TikTok. The Group continues investing resources in a timely manner for improvement of the online sales channels and optimisation of online stores interface so as to capture the change of customer consumption behaviour in the PRC. The Group jointly develops exclusive products with leading e-commerce platforms, and promote AI livestreaming models in various channels to increase brand exposure and livestreaming sales, adopts big data analysis to accurately understand consumer demand, and injects strong momentum into the continued expansion of market scale. To establish an online brand matrix, the Group selected and authorised new online distributors during the year. The Group believes that the online platforms not only serve as business-to-customer trading platforms between the Group and the consumers, but also additional marketing and promotion channels for the brand, which can enhance the overall business potential of the Group.During the year, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series – Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world. Dynasty has won the Silver Medal in the Sparkling Wine/China category, the Silver Medal in the Dry Wine/China category, and the Bronze Medal in the Medium/China category for its Dynasty Tianyang Winery Jasmine Sparkling Wine, Dynasty Inherit Series – Dry Red Wine, and Dynasty Inherit Series – Semi Dry White Wine, respectively, at the 2025 Cathay Global Wine & Spirits Awards Asia (“GWSAA”) (formerly known as the Cathay Hong Kong International Wine & Spirit Competition (“HKIWSC”)). This marks the 15th consecutive year that Dynasty products have won awards at the event, demonstrating industry-wide recognition of Dynasty’s exceptional winemaking skill and quality. In addition, “Dynasty Pinyue VSOP brandy” also won the Gold Medal in the brandy category of 2025 China Fine Wine Challenge.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to 2026, the Group will continue to focus on market and consumer demand, reinvent consumption scenarios and promote product quality. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image as a representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to uphold quality, seize the development trend of low-alcohol and younger consumer markets, and proactively develop new marketing prospects through innovation in products categories and consumption scenarios.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China.For media enquiries:Strategic Financial Relations (China) LimitedMs. Anita Cheung Tel: 2864 4827Ms. Gianna Ye Tel: 2864 4837Ms. Hazel Ye Tel: 2864 4893Ms. Chloe Lyu Tel: 2864 4835Email: sprg-dynasty@sprg.com.hk Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

财务摘要 (经审核)（港币千元）截至十二月三十一日止年度 2025年2024年收入170,011271,372毛利53,382104,720本公司所有者应占溢利13,68833,440每股基本盈利 (港仙)0.972.37香港, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 中国优质葡萄酒生产商王朝酒业集团有限公司(「王朝」或「集团」)(股份代号：00828)今日公布截至2025年12月31日止（「年内」）经审核之全年业绩。2025年，受宏观经济和中国葡萄酒消费市场需求疲弱的情况影响，集团中高档产品销售下滑，收入较去年同比减少37%至1.70亿港元。另外由于销售收入及毛利率下降，以及部分经销商延迟还款导致应收账款亏损拨备增加，本公司所有者应占溢利较去年同比减少59%至13.7百万港元，尽管溢利减少部分已被年内确认的补偿交出净收益所抵消。集团每股基本盈利为每股0.97港仙。随着集团在沿海地区加大对干白葡萄酒市场的推广力度，并推出新款白葡萄酒及起泡酒产品，白葡萄酒产品的销售已成为集团的主要收入来源。红葡萄酒及白葡萄酒产品的销售分别占集团于年内收入的约39%及54%（2024年：分别为约41%及56%）。于2025年，红葡萄酒产品及白葡萄酒产品的毛利率分别为25%及35%（2024年：分别为36%及41%）。整体毛利率减少至31%（2024年：39%），主要由于年内因应市场动态及需求调整产品组合并降低销售价格及利润率。集团积极求新，聚焦「5+4+N产品战略」，其中「N」代表集团推出N项需求定制，不断开拓创新产品，以满足中国不同类型消费群体的多元化需求。年内，集团推出礼盒新品－王朝乙巳蛇年生肖纪念干红葡萄酒，与中国生肖文化相融合，引领「国潮风」，以年轻化的视觉语言呈现生肖文化，吸引潜在消费者。此外，基于其现有的优质产品，集团继续推出新产品并推进产品升级。集团于2025年3月在第112 届全国糖酒商品交易会上推出天阳茶酒系列、王朝百馥VSOP白兰地等新品，以进一步完善其产品矩阵，为消费者提供多元的消费选择。该系列茶香葡萄酒突破传统葡萄酒的局限，以「茶酒融合」为核心理念，凭借独特的酿造工艺迅速获得市场目光。在全国糖酒商品交易会期间，集团亦举办品酒会，而王朝宁夏酒庄的新品凭借独特的风味和精湛的酿造工艺，赢得业界的好评。下半年，集团亦因应市场需求，推出全新产品「嗨」茶风味酒系列，非常适合年轻消费者的即饮场景。除了丰富产品矩阵外，集团与经销商紧密合作，积极推进市场推广活动，加速创新消费场景，提升及强化葡萄酒文化体验。集团于各类展览及葡萄酒博览会举行期间，举办了全国巡回品鉴会及招商活动、新品发布会以及香港上市20周年推广活动，期间集团大力推广其全系列的最新产品组合。年内，集团批准设立的两间合资公司于2025年2月成立，分别从事黄酒及陈皮酒生产及销售，以及于全国范围内买卖酱香型白酒产品。对于黄酒项目，江苏的一座储罐容量为3,000 吨黄酒及特种黄酒－陈皮酒的生产设备及安装及测试预期将于2026年下半年完成建设。于项目完成后，集团将能够生产特种黄酒－东台陈皮酒，让集团可有效扩展产品品类，把握中国黄酒行业的发展机遇，进一步优化集团产业布局，拓展品类版图，实现王朝向全品类、全产业链企业的转型。对于酱香型白酒领域，王朝酱香型白酒产品，即「汉」、「唐」、「宋」、「明」，已于天津及上海核心市场新推出，并将于2026年进一步战略推广至其他地区。酱香型白酒产品满足不同消费习惯的客户群体的需求，并为集团业务作出贡献。未来，酱香型白酒产业的持续发展及扩张及客户群体水平的提升，必将有效推动王朝葡萄酒及相关产品销售规模的增长，从而提升行业影响力及品牌知名度。电商销售方面，集团的电商团队于传统电商平台全面运营在线商店销售产品，例如京东商城、天猫商城及拼多多，以及通过兴趣电商平台（包括小红书app、快手app 及抖音app）全面创新品牌、品类、业务体系、流程和模式。集团继续为改善网上销售渠道及时投入资源，优化在线商店界面，以把握中国客户消费行为的变化，与头部电商平台共同开发专属产品，并通过多种渠道推广人工智能直播模型以提升品牌曝光度及直播销售额，采用大数据分析以精准洞察消费者需求，为市场规模持续扩大注入强劲动力。为建立在线品牌矩阵，集团于年内甄选及开放新店在线经销商授权。集团相信线上平台不仅是集团与消费者之间的企业对客户交易平台，亦是品牌新增的市场推广及宣传渠道，从而提升集团的整体业务潜力。年内，集团在大型葡萄酒品鉴大赛中屡获殊荣。在多个奖项中，「王朝锦邑桶藏12年XO白兰地」荣获2025年国际葡萄酒与烈酒大赛（「IWSC」）中的银奖。该比赛被视为葡萄酒和烈酒质量的国际评价标准。王朝百馥VSOP白兰地、金王朝马瑟兰干红葡萄酒以及天阳茶酒系列亦于中国酒业协会举办的「二零二四年青酌奖」各类别评选中获奖。「王朝梦园白葡萄酒」亦以其卓越的酒质荣获2025年春季FIWA法国国际葡萄酒大奖赛中国区金奖。此外，「王朝传承系列－干红葡萄酒」于同一比赛中荣获金奖。该等葡萄酒因其酒香优雅、酒体顺滑和口感圆润从众多参赛作品中脱颖而出，并在比赛中获得奖项，向国家及世界展示了王朝葡萄酒的魅力和实力。王朝旗下产品「王朝天阳酒庄茉莉葡萄起泡酒」、「王朝传承干红葡萄酒」以及「王朝传承半干白葡萄酒」分别于2025年度国泰环球葡萄酒及烈酒大奖亚洲（「GWSAA」）（前称国泰航空香港国际美酒品评大奖（「HKIWSC」））荣获中国产区品评组别下气泡酒、干型酒银奖殊荣，以及中国产区品评组别下半干型酒铜奖殊荣。这是王朝产品连续15年于该奖项中获得佳绩，标志着王朝在葡萄酒酿造技艺与卓越质量方面再次获得业界的高度认可。此外，「王朝品悦VSOP白兰地」在2025年中国优质葡萄酒挑战赛中荣获白兰地类别金奖。王朝主席万守朋先生总结︰「展望2026年，本集团将继续以市场及消费者需求为导向，重塑消费情景，提升产品质量。同时，本集团将继续创新市场营销策略，激发品牌活力，进一步扩大王朝产品的市场占有率，加强王朝品牌作为国产葡萄酒代表的形象，并为中国葡萄酒行业树立标杆，将王朝美酒风尚带给更多的中国消费者。本集团将继续秉持质量至上，把握低酒度饮品及年轻消费者市场的发展趋势，并通过产品品类及消费场景的创新，积极开拓新的市场前景。」关于王朝酒业集团有限公司王朝酒业集团有限公司于2005年1月26日在香港联合交易所有限公司主板上市，股份代号00828。成立于1980年，王朝为中国优质葡萄酒生产商，主要生产及销售「王朝」商标的葡萄酒产品，是中国第一家中外合资的酿酒企业，主要股东包括天津食品集团有限公司及法国葡萄酒巨头人头马集团。集团产销葡萄酒产品系列超过100种，及引入进口葡萄酒产品，为国内各消费层提供高质素及物超所值的葡萄酒。新闻垂询：纵横财经公关顾问(中国)有限公司张丽云小姐 电话：2864 4827叶甘霖小姐 电话：2864 4837叶婉铃小姐 电话：2864 4893吕昕纯小姐 电话：2864 4835电邮：sprg-dynasty@sprg.com.hk Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

IGG Inc 2025 Annual Financial Highlights and 2026 Business Update:- In 2025, the Group maintained stable operations, achieving revenue of HK$5.5 billion, representing a modest year-on-year decrease of 4%. Mid-generation titles “Doomsday: Last Survivors” and “Viking Rise” delivered steady revenue growth, generating approximately HK$1.14 billion and HK$720 million, respectively, representing year-on-year increases of 12% and 6%. The APP Business achieved revenue of HK$1.06 billion. “Lords Mobile”, IGG’s flagship title launched ten years ago, made a significant contribution of HK$2.17 billion in revenue.- The Group achieved net profit of nearly HK$590 million in 2025, representing a year-on-year increase of 1%. Net profit from the Group’s core business amounted to approximately HK$570 million, while profit from investments contributed approximately HK$20 million.- The Group has consistently prioritized returns to shareholders and increased dividend payout for the second half of 2025. The Board of Directors declared a second interim dividend of HK6.7 cents per ordinary share, and a special dividend of HK47.7 cents per ordinary share, totalling HK54.4 cents per ordinary share. The Group allocated approximately HK$890 million for share buy-backs and dividends in 2025, which corresponds to approximately 152% of annual profit.- Entering 2026, the mid-generation title “Doomsday: Last Survivors” continues its upward trajectory, achieving record monthly gross billings of HK$130 million starting from December last year, with strong performance expected to continue. New game “Fate War” has built solid momentum and is poised for further growth.HONG KONG, Mar 25, 2026 - (ACN Newswire via SeaPRwire.com) – IGG Inc (“IGG” or “the Group”, stock code: 799.HK), a leading global developer and operator of mobile games and applications, is pleased to announce the audited consolidated financial results of the Group for the year ended 31 December 2025.In 2025, the Group recorded a stable annual revenue of HK$5.5 billion. Despite a slight year-on-year fluctuation in revenue, the Group successfully maintained full-year profit at nearly HK$590 million (comprising approximately HK$570 million in net profit from the Group’s core business (non-IFRS measure) and approximately HK$20 million from investments) through refined management and business structure optimization, demonstrating strong profitability and risk resilience. Notably, mid-generation titles “Doomsday: Last Survivors” and “Viking Rise” maintained solid momentum and achieved new revenue highs in their third year of operation. In 2025, “Doomsday: Last Survivors” and “Viking Rise” contributed approximately HK$1.14 billion and HK$720 million, respectively, representing year-on-year increases of 12% and 6%. The APP Business generated revenue of HK$1.06 billion. Together, these three contributors accounted for 53% of the Group’s revenue in 2025, reflecting the continued success of its diversified growth strategy. In addition, “Lords Mobile”, IGG’s flagship title, reached its 10-year milestone and made a significant contribution of HK$2.17 billion in revenue. During the year, revenue from Asia, Europe and North America accounted for 41%, 36% and 19%, respectively, of the Group’s total revenue. As at 31 December 2025, the Group’s mobile games were available in 23 different languages worldwide, with approximately 1.6 billion users in total and nearly 17 million monthly active users (“MAU”) across more than 200 countries and regions.“Lords Mobile”, IGG’s blockbuster title, reached its 10-year milestone during the year. It is the Group’s first cross-platform, multi-language game that integrates strategy, role-playing, and real-time competitive gameplay. Lauded by Sensor Tower for its longevity, it is designed for a global audience. It has received widespread acclaim from gamers, and consistently generates stable revenue for the Group. During the year, “Lords Mobile” launched a series of IP collaborations, including the film “Pacific Rim”, the game “Angry Birds”, and, more recently, original fantasy characters created by “tokidoki” co-founder and artist Simone Legno, injecting renewed vitality and immersive gameplay. As the bedrock of the Group’s operations, “Lords Mobile” delivered revenue of HK$2.17 billion, consistently contributing stable cash flow to the Group.After over three years of cultivation, the Group’s two growth drivers, “Doomsday: Last Survivors” and “Viking Rise” delivered solid results with revenue growing 12% and 6% year-on-year respectively, against market trends. Their lifecycles have also surpassed industry norms. During 2025, “Doomsday: Last Survivors” enhanced gameplay through the launch of new battlefield and squad equipment features. The game also collaborated with the renowned manga IP “Attack on Titan” which was well-received by its nearly 100 million users. In 2025, the game contributed revenue of HK$1.14 billion. The title continued its upward trajectory, with monthly gross billings reaching record highs starting from December at HK$130 million, demonstrating strong user engagement and future growth.“Viking Rise”, the Group’s other mid-generation Viking-themed title, also contributed solid results. During 2025, the game introduced hybrid-casual combat gameplay, collaborated with renowned IP “How to Train Your Dragon (Live Action)”, and rolled out offline competitions to strengthen engagement and social interaction among players. As of 31 December 2025, the game had 67 million registered users and revenue of HK$720 million, representing a 6% year-on-year increase.“Fate War”, a new strategy game released in 2025, established a new growth trajectory. Upon launch, the game was prominently featured on Apple’s App Store and Google Play Store worldwide because of its unique blend of simulation and strategy gameplay. This recognition validates the title’s exceptional quality and builds strong momentum for future revenue growth. As of 31 December 2025, the game achieved monthly gross billing of HK$30 million, with approximately 4.7 million registered users and 1.2 million monthly active users.Leveraging its global operational expertise and a base of more than 1 billion users, the Group established a second growth curve through its APP Business. Contributing 19% of the Group’s revenue, this business validates the Group’s user acquisition and monetization capabilities beyond gaming, delivering genuine business diversification. In 2025, it generated revenue of HK$1.06 billion and net profit of over HK$100 million. During the year, the APP Business had more than 67 million monthly active users, representing a year-on-year increase of 8%.The Group consistently prioritizes shareholder returns. In light of the Group’s solid financial position and its sustained long-term development, the Board of Directors has resolved to materially increase shareholder distributions, declaring a total dividend (including a second interim dividend and a special dividend) of HK54.4 cents per ordinary share. Aggregate shareholder returns for 2025 (encompassing dividends and share buybacks) totalled HK$890 million, constituting 152% of annual profit. This elevated distribution ratio serves as a clear testament to management's confidence in the Company's cash generation capacity and future growth potential. Looking ahead to 2026, the Group has established a solid foundation for growth: the core gaming portfolio continues to serve as a strong growth driver, with “Doomsday: Last Survivors” expected to maintain its strong performance trajectory; “Fate War”, the Group’s new title, is entering a harvest period and will progressively generate enhanced revenue contributions; and the APP Business represents a well-defined secondary growth curve. The Group will continue to deepen its global operational excellence and advance the coordinated development of its diversified product matrix, with the objective of generating enduring, sustainable value for shareholders.[1] APP Business: development and operations of the Group’s mobile applications.[2] Net profit for core business (non-IFRS measure): net profit excluding gain/loss on investments. Gain/loss on investments including: (1) fair value change and gain/loss on disposal of other financial assets or liabilities and assets held for sale, and dividend income; and (2) share of results of associates and joint ventures, impairment loss on interest in associates and joint ventures and net gain/loss on disposal and deemed disposal of associates and joint ventures.[3] Monthly gross billing as of December 31, 2025 and January 31, 2026[4] “Lords Mobile” was awarded “Best Evergreen Strategy Game” at the Sensor Tower APAC Awards 2025.[5] User data as of December 31, 2025[6] Monthly gross billing for December 2025About IGG IncEstablished in 2006, IGG Inc is a leading global developer and operator of mobile games and applications, with headquarters in Singapore and local offices in the United States, China, Canada, Japan, South Korea, Thailand, the Philippines, Indonesia, Brazil, Türkiye, Italy and Spain. IGG offers multi-language and multifarious games and mobile applications to users around the world. The Group has established long-term partnerships with over 100 business partners, including global platforms, advertising channels, and vendors such as Apple, Google and Meta. IGG’s most popular games include “Lords Mobile”, “Doomsday: Last Survivors”, “Viking Rise”, “Time Princess”, “Fate War”, along with a diverse range of mobile applications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - The Census and Statistics Department today released the latest external merchandise trade statistics. In February 2026, the total value of merchandise exports increased by 24.7% year-on-year to $408.8 billion. For the first two months of 2026, the total value of exports of goods amounted to $928.3 billion, marking an increase of 29.6% from the same period of last year.Hong Kong Trade Development Council’s Director of Research Bruce Pang said, over the past few months, Hong Kong’s external trade has continued to exhibit clear growth momentum. Although global geopolitical conditions remain tense, underlying demand from the Chinese Mainland and major overseas markets has remained resilient. We maintain a positive outlook, yet remain cautious in regard to Hong Kong’s trade performance.”HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, N.Y., Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - OpenClawd AI today released a security-focused platform update that adds automated skill vetting, verified installer sourcing, and runtime sandboxing to its managed OpenClaw hosting service. The update responds to two converging threats targeting users of the open-source AI agent formerly known as Clawdbot and Moltbot: a large-scale malware campaign inside the official OpenClaw skill marketplace, and a parallel wave of counterfeit installation packages being promoted through search engine results.The numbers are bad enough on their own. Together, they describe a supply chain that is actively hostile to casual users.One in Eight OpenClaw Skills Is Confirmed MaliciousIndependent security researchers recently completed an audit of the ClawHub skill marketplace — the primary distribution channel for third-party OpenClaw plugins. Out of 2,857 published skills, 341 were confirmed as malicious. That is approximately 12% of the entire marketplace.The findings include:Keyloggers and credential stealers deployed through skills that appear to offer legitimate productivity featuresSilent data exfiltration — one widely-downloaded skill was found to instruct the OpenClaw agent to execute curl commands that sent user data to an external server without any notification or consent promptPrompt injection payloads embedded in skill descriptions, designed to override the agent’s safety guidelines and force execution of unauthorized commandsPlaintext credential exposure — a separate audit found that over 280 additional skills were leaking API keys, tokens, and passwords in their source codeA major cybersecurity firm tested a specific ClawHub skill and published the results: nine security findings, including two critical and five high-severity issues. The skill functioned as what the researchers called “functionally malware.” The most widely-downloaded malicious skill on ClawHub was a cryptocurrency stealer.Fake OpenClaw Installers Are Being Promoted by Search EnginesThe marketplace problem is only half the story. A cybersecurity research team discovered that threat actors have published counterfeit OpenClaw installation packages on open-source code repositories. These fake installers mimic the legitimate OpenClaw setup process but instead deliver a malware packer that disables firewall protections and routes network traffic through compromised systems.The attack chain is straightforward: a user searches for “install OpenClaw” or “Clawdbot download.” An AI-powered search engine returns a result linking to the malicious repository. The user follows the instructions. The malware deploys silently.The researcher who discovered the campaign noted that the person who first reported the threat was a technical professional. “If a fellow IT pro is susceptible to this threat,” he said, “then anyone could be.”“There are now two ways to get compromised before you even run your first OpenClaw command,” said Danny Wilson, spokesperson for OpenClawd. “You can install a fake version of the software, or you can install the real version and then add a skill that steals your data. We built this update so that neither path exists on our platform.”What OpenClawd Ships TodayThis update targets both the supply chain and the runtime:Verified installer sourcing — all OpenClawd instances are provisioned from cryptographically signed OpenClaw releases, pulled directly from the official repository. No third-party install paths. No search engine intermediaries.Skill vetting pipeline — third-party skills go through automated static analysis and behavioral testing before activation. Skills flagged for network exfiltration, prompt injection patterns, or credential exposure are blocked by default.Runtime sandboxing — each skill executes in an isolated environment with explicit permission boundaries. A skill that requests network access to an unexpected endpoint triggers a review before execution.Credential isolation — API keys and tokens are stored in encrypted vaults and never exposed in plaintext to skill code or agent logsAutomatic CVE patching — hosted instances track the latest stable OpenClaw release (currently v2026.3.x), with all known vulnerabilities patched before deploymentOpenClawd does not operate its own skill marketplace. Skills available on hosted instances are drawn from the official ClawHub repository after passing the vetting pipeline described above.OpenClawd is not affiliated with the OpenClaw open-source foundation, OpenAI, Peter Steinberger, or any third-party security research firm cited in this release. It is an independent platform built on the open-source Clawdbot codebase. The open-source project remains free at github.com/openclaw/openclaw.Pricing starts with a free tier. Paid plans include dedicated compute, priority security patching, and uptime monitoring. Deploy a secure OpenClaw instance at https://openclawd.ai.Contact:Email: support@openclawd.ai Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Development Highlights- During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa N01 for Injection).- In 2025, the Group’s sales of innovative products reached RMB 15.22 billion, representing a year-on-year increase of 26.2%. In addition, the Group has established multiple R&D centers in Shanghai, Nanjing, Beijing, Guangzhou, and other cities, and has successfully built diversified innovative technology platforms covering small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalable formulations, transdermal patches and other fields.- As at 31 December 2025, the Group had a total of 39 innovative oncology drug candidates, 10 innovative liver/cardiometabolic drug candidates, 14 innovative respiratory/autoimmune drug candidates, and 6 innovative surgery/analgesia drug candidates in the process of clinical trial application or above. Of these, 1 innovative oncology drug candidate and 2 innovative surgery/analgesia drug candidates are in the marketing application stage; and 13 innovative oncology drug candidates, 1 innovative liver/cardiometabolic drug candidate, 5 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate are in Phase III clinical trials. Also, 9 innovative oncology drug candidates, 6 liver/cardiometabolic drug candidates, 5 innovative respiratory/autoimmune drug candidates, and 2 innovative surgery/analgesia drug candidates are in Phase II clinical trials. In addition, the Group had a total of 16 innovative oncology drug candidates, 3 innovative liver/cardiometabolic drug candidates, 4 innovative respiratory/autoimmune drug candidates, and 1 innovative surgery/analgesia drug candidate in Phase I clinical trials.- Focus V(R) (Anlotinib Hydrochloride Capsules) is a novel small molecule multi-target tyrosine kinase inhibitor that has been approved for 10 indications. It has several new indications currently in Phase III clinical studies, including first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, with plans to gradually submit marketing applications within the next two years.- From 2023 to 2025, the Group obtained marketing approval for 7 national category 1 innovative oncology drugs, namely, Saitanxin(R) (Culmerciclib capsule), Hernexeos(R) (Zongertinib table), Yilishu(R) (Efbemalenograstim alfa Injection), Andewei(R) (Benmelstobart Injection), Anboni(R) (Unecritinib Fumarate Capsules), Anluoqing(R) (Envonalkib Citrate Capsules), and Anfangning(R) (Garsorasib Tablets). It also obtained marketing approval for 4 oncology biosimilars, including Anbeisi(R) (Bevacizumab Injection), Delituo(R) (Rituximab Injection), Saituo(R) (Trastuzumab for Injection), and Paletan(R) (Pertuzumab Injection). The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.- Tianqing Ganmei(R) (Magnesium Isoglycyrrhizinate Injection) is the fourth-generation of glycyrrhizic acid preparation that has been approved for 3 indications. During the Year, the Group made efforts to strengthen academic promotion, expanding doctor coverage and gaining recognition from experts through academic conferences at all levels, while vigorously exploring new patients to expand into new markets, and actively promoting retrospective research to provide more academic evidence for its clinical use.- TQC3721 (PDE3/4 inhibitor) is a dual PDE3/4 inhibitor currently undergoing Phase III clinical trials in China for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The Group is developing a variety of dosage forms of TQC3721: a suspension for inhalation is in Phase III clinical trials, and an inhaled dry powder formulation is in Phase II clinical trials. The different dosage forms are expected to further enhance patient compliance.- Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) is the first domestically produced cataplasms approved for marketing in China, ranking first in the market share of topical analgesia for many years. The Group focuses on the development of highpotential regions, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand, driving the sustained rapid sales growth of Zepolas/Debaian. The second-generation flurbiprofen patch developed by the Group is expected to be approved for marketing within one year. With formulation enhancements, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.HONG KONG, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX stock code:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2025 (the “Year”).During the Year, the Group's revenue increased by approximately 10.3% to approximately RMB31.83 billion. Profit attributable to owners of the parent from continuing operations (as reported) was approximately RMB2.34 billion, a year-on-year increase of approximately 22.0%. Basic earnings per share attributable to owners of the parent from the continuing operations were approximately RMB13.02 cents, an increase of approximately 24.0% over last year. Underlying profit attributable to owners of the parent totaled approximately RMB4.54 billion, a year-on-year increase of approximately 31.4%. The Group’s liquidity remained strong, with cash and bank balances classified as current assets of approximately RMB12.18 billion, bank deposits classified as non-current assets of approximately RMB10.25 billion, wealth management products of approximately RMB10.56 billion in total, and total fund reserves of approximately RMB32.99 billion for the Year.The Board of Directors has recommended a final dividend payment of HK5 cents per share (2024: HK4 cents). Together with an interim dividend of HK5 cents already paid, the total dividend for the year amounts to HK10 cents (2024: HK7 cents).Sales: Innovation-driven growth fuels sustained sales momentumDuring the Year, the Group consistently increased investments to enhance R&D quality and efficiency, which led to a marked strengthening of R&D capabilities, driving sustained sales revenue growth and delivering substantial results. Sales of innovative products increased by 26.2% year-on-year to approximately RMB15.22 billion, accounting for approximately 47.8% of the Group’s revenue. If the sales is categorized by therapy field, sales of oncology drugs increased by 22.8% year-on-year to approximately RMB13.18 billion, accounting for approximately 41.4% of the Group's revenue. Sales of surgical/analgesic medications increased by 12.8% year-on-year to approximately RMB5.03 billion, accounting for approximately 15.8% of the Group's revenue.In the field of oncology, the Group has a comprehensive layout in non-small cell lung cancer (NSCLC), covering the full-line treatment of multiple subtypes. Focus V(R) (Anlotinib Hydrochloride Capsules) has been approved for 10 indications, and several new indications are currently in the marketing application or Phase III clinical trial stage. Its combination therapy has demonstrated superior efficacy in the treatment of lung cancer. From 2023 to 2025, the Group obtained approval for and launched a total of 7 national category 1 innovative oncology drugs and 4 oncology biosimilars. The sales volume of these products accelerated rapidly in 2025, and they have become important contributors to the Group’s revenue growth.In the field of surgery/analgesia, Zepolas(R)/Debaian(R) (Flurbiprofen Cataplasms) have ranked first in market share of topical analgesia for many years. The second-generation flurbiprofen patch is anticipated to receive marketing approval within the year and is expected to strengthen its market leadership through this dosage form upgrade. Meanwhile, Putanning(R) (Meloxicam Injection (II)), China’s first once-daily long-acting analgesic NSAIDs injection, was approved for marketing by the NMPA and the FDA in May 2025 and has been included in the NRDL in 2025. It is expected to become another blockbuster product for the Group in pain management area.R&D: Technology-driven advancements significantly enhance R&D quality and efficiency R&D innovation has always been the key driving force of the Group. The Group has established multiple R&D centers in places including Shanghai, Nanjing, Beijing, and Guangzhou, and has successfully built diversified innovative technology platforms covering such fields as small molecules, protein degraders, siRNA, monoclonal/bispecific antibodies, antibody-drug conjugates (ADC), inhalation formulations, and transdermal patches. For the year ended 31 December 2025, the Group’s total R&D investment amounted to approximately RMB 6.32 billion, accounting for approximately 19.8% of Group revenue.The Group also attaches tremendous importance to the protection of intellectual property rights and actively files patent applications to enhance its core competitiveness. During the Year, the Group filed 1,167 new patent applications and received 273 patent grants. As at the end of the Year, the Group had accumulated 5,724 valid patent applications and obtained 2,120 valid patent grants.Prospects: Focusing on innovation and firmly promoting internationalization strategyLooking ahead, the Group will continue to focus on innovation and remain deeply committed to four core therapeutic areas – oncology, liver / cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. It will leverage AI to deeply empower the entire R&D process and continuously strengthen its R&D and innovation capabilities to drive steady business growth. Over the next three years (2026-2028), the Group’s innovation pipeline is expected to experience another wave of explosive growth, with nearly 20 national category 1 innovative drugs expected to be approved for marketing, including multiple blockbuster products with first-in-class (FIC) and best-in-class (BIC) potential. It is expected that by the end of 2028, the total number of innovative products launched by the Group will be around 40, positioning them as the core driver of business growth.At the same time, the Group will firmly advance its internationalization strategy. In February 2026, the Group announced that it had granted Sanofi an exclusive worldwide license to develop, manufacture, and commercialize Rovadicitinib, with the right to receive payments of up to US$1.53 billion, plus tiered royalties of up to double digits based on annual net sales of Rovadicitinib. Going forward, out-licensing will become another important source of revenue for the Group, continuously injecting strong, new momentum into its performance growth and formally launching a second growth curve supported by revenue from internationalization. In addition, the Group remains committed to adhering to the "win-win cooperation" philosophy and is dedicated to building an open and diverse innovation ecosystem. Through in-depth cooperation with the world's leading pharmaceutical companies, biotechnology firms and scientific research institutions, the Group is accelerating the aggregation of high-quality global resources, promoting the co-creation and sharing of innovative outcomes, and continuously strengthening its market leadership. Through the integration of high-quality resources such as LaNova Medicines and Hygieia, the Group has significantly strengthened its R&D capabilities in cutting-edge fields, including tumor immunology and siRNA.Looking ahead, the Group will continue to drive innovation through its dual engines of internal R&D and strategic cooperation, accelerate its development through internationalization, and make steady progress towards its strategic goal of becoming a world-class innovative pharmaceutical company.For detailed information on the Group’s results for the Year, please refer to the official announcements uploaded by the Group to the Hong Kong Stock Exchange website and its official website.About Sino Biopharmaceutical Limited (HKEX:1177)Sino Biopharmaceutical Limited, together with its subsidiaries, is a leading, innovative R&D-driven pharmaceutical group in China. Its business covers the entire industrial chain, including R&D platforms, intelligent manufacturing, and a robust sales system. Its products encompass a wide range of biologics and chemical drugs, with a strong presence in four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia. The company was listed on the Hong Kong Stock Exchange in 2000, was included as a constituent of the MSCI China Index in 2013, became a constituent of the Hang Seng Index in 2018, and was added to the Hang Seng Stock Connect Biotech 50 Index and the Hang Seng China (Hong Kong-listed) 25 Index in 2020. The company has been named among the "Top 50 Global Pharmaceutical Companies" by the authoritative U.S. magazine Pharm Exec for seven consecutive years, and has been recognized as one of the "Top 50 Best Companies in Asia" by Forbes Asia for three consecutive years.For more information, please visit: www.sbpgroup.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

重点成果- 年内，集团共有4个创新产品获NMPA批准上市，分别为赛坦欣(R)（库莫西利胶囊）、圣赫途(R)（宗艾替尼片）、普坦宁(R)（美洛昔康注射液(II)）和安启新(R)（注射用重组人凝血因子VIIa N01）。- 2025年，集团创新产品收入达到人民币152.2亿元，同比增长26.2%。此外，集团已在上海、南京、北京、广州等地建立多个研发中心，并成功构建了涵盖小分子、蛋白降解剂、siRNA、单抗／双抗、抗体偶联药物（ADC）、吸入制剂、透皮贴剂等领域的多元化创新技术平台。- 截至2025年12月31日，集团共有39个肿瘤领域、10个肝病╱心血管代谢领域、14个呼吸╱自免领域、和6个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，1个肿瘤领域、2个外科╱镇痛领域产品处在上市申请阶段；13个肿瘤领域、1个肝病╱心血管代谢领域、5个呼吸╱自免领域、1个外科╱镇痛领域的创新候选药物处于临床III期，9个肿瘤领域、6个肝病╱心血管代谢领域、5个呼吸╱自免领域、2个外科╱镇痛领域的创新候选药物处于临床II期，另有16个肿瘤领域、3个肝病╱心血管代谢领域、4个呼吸╱自免领域、1个外科╱镇痛领域的创新候选药物处于临床I期。- 福可维(R)（盐酸安罗替尼胶囊）是一款新型小分子多靶点酪氨酸激酶抑制剂，目前已获批10项适应症，其一线非鳞状非小细胞肺癌、一线胰腺癌等多项新适应症正在开展III期临床研究，预计未来两年将逐步递交上市申请。- 2023-2025年，集团共有7款肿瘤领域的国家1类创新药获批上市，分别为：赛坦欣(R)（库莫西利胶囊）、圣赫途(R)（宗艾替尼片）、亿立舒(R)（艾贝格司亭α注射液）、安得卫(R)（贝莫苏拜单抗注射液）、安柏尼(R)（富马酸安奈克替尼胶囊）、安洛晴(R)（枸橼酸依奉阿克胶囊）和安方宁(R)（格索雷塞片）；以及4款肿瘤领域的生物类似药获批上市，分别为：安倍斯(R)（贝伐珠单抗注射液）、得利妥(R)（利妥昔单抗注射液）、赛妥(R)（注射用曲妥珠单抗）和帕乐坦(R)（帕妥珠单抗注射液）。该等产品在2025年快速放量，成为集团收入增长的重要贡献品种。- 天晴甘美(R)（异甘草酸镁注射液）是第四代甘草酸制剂，目前已获批3个适应症。集团年内着力加强学术推广，透过各层级的学术会议增强了医生覆盖和专家认可，同时大力发掘新患者拓展新市场，并积极推进回顾性研究，为其临床使用提供更多的学术证据。- TQC3721（PDE3／4抑制剂）是一款PDE3／4双重抑制剂，目前正在中国开展III期临床试验，用于治疗中重度慢性阻塞性肺病（COPD）。集团正在开发TQC3721的多种剂型：吸入用混悬液位于III期临床阶段，吸入粉雾剂位于II期临床阶段，有望透过多种剂型进一步提升患者的依从性。- 泽普思(R)／得百安(R)（氟比洛芬凝胶贴膏）是中国首个获批上市的国产凝胶贴膏，连续多年蝉联外用镇痛市场份额第一位。集团聚焦高潜力地区开发，深入拓展市场覆盖，并逐步扩大产能以满足市场的旺盛需求，推动泽普思／得百安销售额持续快速增长。集团开发的第二代氟比洛芬贴剂预计将在年内获批上市，透过剂型升级，二代产品可显著提高药物透皮吸收度，增强贴膏粘附性，从而提升患者的依从性。香港, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 中国领先的创新研发驱动型医药集团-中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2025年12月31日止12个月（「年内」）之经审核财务业绩。年内，集团收入增长约10.3%至约318.3亿元（人民币，下同）。来自持续经营业务之归属于母持有者盈利（财务报表所示）约23.4亿元，按年增长约22.0%。来自持续经营业务之归属于母公司持有者盈利计算之每股基本盈利约人民币13.02分，较去年增加约24.0%。归属于母公司持有者之基本溢利约45.4亿元，按年增长约31.4%。集团流动资金保持充裕，年内有计入流动资产之现金及银行结余约121.8亿元、计入非流动资产之银行存款约102.5亿元，理财管理产品总额约105.6亿元，资金储备总额约329.9亿元。董事会建议派发末期股息每股5港仙（2024年：4港仙），连同已派发中期股息每股5港仙，全年合共派发股息每股10港仙（2024年：7港仙）。销售：创新引领，销售动能持续释放年内，集团持续加大投入以提升研发质效，研发实力显著增强，驱动销售收入持续增长，成果丰硕。年内，创新产品之收入同比增加26.2%，达约152.2亿元。至于分治疗领域，抗肿瘤用药之收入同比增加22.8%，达约131.8亿元，占集团收入约41.4%。外科／镇痛用药之收入同比增加12.8%，达约50.3亿元，占集团收入约15.8%。肿瘤领域，集团全面布局非小细胞肺癌领域，覆盖多种分型的全线治疗，福可维(R)（盐酸安罗替尼胶囊）已获批10项适应症，多项新适应症处于上市申请或III期临床阶段，其联合疗法在肺癌治疗中展现出优效。2023年至2025年间，集团共有7款肿瘤领域的国家1类创新药以及4款肿瘤领域的生物类似药获批上市，该等产品在2025年快速放量，成为集团收入增长的重要贡献品种。于外科╱镇痛领域，泽普思(R)／得百安(R)（氟比洛芬凝胶贴膏）连续多年蝉联外用镇痛市场份额第一位，第二代氟比洛芬贴剂预计将在年内获批上市，有望透过剂型升级巩固市场领先地位。同时，中国首款一日一次长效镇痛NSAIDs注射液普坦宁(R)（美洛昔康注射液（II））已于2025年5月获得NMPA和FDA的上市批准，并已被新增纳入2025年国家医保药品目录，有望成为集团镇痛领域的又一款重磅产品。研发：技术筑基，研发质效显著提升研发创新始终是集团的核心驱动力，集团目前已在上海、南京、北京、广州等地建立多个研发中心，并成功构建了涵盖小分子、蛋白降解剂、siRNA、单抗／双抗、抗体偶联药物（ADC）、吸入制剂、透皮贴剂等领域的多元化创新技术平台。截至二零二五年十二月三十一日止年度，研发总投入约人民币63.2亿元，占集团收入约19.8%。集团亦重视保护知识产权，积极申报各项专利，以提高核心竞争力。年内，集团提交专利申请1,167项、获得专利授权273项。截至年末，集团累计有效专利申请达5,724项，累计有效专利授权达2,120项。展望：聚焦创新，坚定推进国际化战略展望未来，集团将继续聚焦创新，深耕肿瘤、肝病／心血管代谢、呼吸／自免、外科／镇痛四大核心治疗领域，以AI深度赋能研发全流程，持续强化创新研发能力推动业绩稳步增长。预计未来三年（2026-2028年），集团创新管线将迎来新一轮爆发式增长，预计近20款国家1类创新药有望获批上市，涵盖多款具备全球同类首创 (FIC) ／同类最佳 (BIC) 潜力的重磅产品。预计至2028年底，集团上市创新产品总数将达到近40款，成为驱动业绩增长的核心引擎。同时，集团坚定推进国际化战略。2026年2月，集团宣布授予Sanofi在全球范围内开发、生产及商业化罗伐昔替尼的独家许可，并有权获得最高15.3亿美元的付款，以及基于罗伐昔替尼年度净销售额的高达双位数的销售提成。未来，对外授权合作将成为集团的又一重要收入来源，持续为业绩增长注入强劲新动能，正式开启以国际化收入为支撑的第二增长曲线。此外，集团始终秉持「合作共赢」理念，着力构建开放多元的创新生态体系。透过与全球顶尖药企、生物科技公司及科研机构的深度合作，集团正加速汇聚全球优质资源，推动创新成果的共创共享，持续巩固市场领导地位。透过整合礼新医药、赫吉亚等优质资源，集团在肿瘤免疫及siRNA等前沿赛道的研发实力显著增强。未来，集团将继续以自主研发与战略合作双引擎驱动创新，以国际化加速发展，向世界级创新医药企业的战略目标稳步迈进。有关集团本年度详细业绩资料，请参阅集团上载至香港联合交易所及官网之正式公告。有关中国生物制药有限公司（股票编号：1177）中国生物制药，连同其附属公司，是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智慧化生产和强大销售体系全产业链。产品包括多种生物药和化学药，在肿瘤、肝病／心血管代谢、呼吸／自免、外科／镇痛四大治疗领域处于优势地位。公司于2000年在香港联交所上市，2013年入选MSCI全球标准指数之中国指数成分股；2018年入选恒生指数成分股；2020年入选恒生沪深港通生物科技50指数成分股、恒生中国(香港上市)25指数。中国生物制药连续七年荣登美国权威杂志《制药经理人》发布的「全球制药企业TOP50」，连续三年获评《福布斯》(亚洲) 「亚太最佳公司50强」。有关中国生物制药的进一步资料，请浏览: www.sbpgroup.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 26, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA) founded in 1890, today announced the launch of its Global Polo Shirt Campaign, An Icon Born from the Game. The global campaign is a powerful tribute to the iconic polo shirt's authentic sports origins and its evolution into one of the world's most enduring style essentials.U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player Nico Escobar takes in the game atop his equine partner, wearing polo whites and a classic navy U.S. Polo Assn. polo shirt, An Icon Born from the GameU.S. Polo Assn. models in polo shirts at the Spring-Summer 2026 Global Collection Photoshoot in Charleston, South Carolina‘The Polo Shirt: An Icon Born From the Game' campaign imagery featuring U.S. Polo Assn. modelsThe polo shirt's beginning was born on the polo fields, shaped by motion, competition, and the spirit of the game for which it was named. From its earliest days, the polo shirt was designed with purpose, worn by players seeking performance on the polo fields. Today, U.S. Polo Assn. celebrates this timeless favorite, not just as a fashion item, but as an icon born from sport and carried forward through generations of players and consumers all over the world.The polo shirt is one of the most iconic essentials dating back over 100 years, notable for its unique fusion of sport and style. Originally designed with breathable pique knit, a soft collar, and lightweight construction to meet the demands of competitive sports, it has evolved into a timeless essential, suitable for casual elegance and leisurewear.The polo shirt traces its origins to polo players, where it was created out of necessity for the sport. Polo players modified long‑sleeved cotton shirts to better handle heat, movement, and wind while playing. These functional, sport‑driven adaptations represent the earliest form of what would become the polo shirt. In the early 20th century, polo players helped formalize these functional elements as the sport gained popularity, reinforcing the shirt's connection to the sport and its functional design.Over the years, the polo shirt became a cornerstone of casual sportswear around the world, symbolizing preppy style, luxury leisure culture, and contemporary athleisure, seamlessly transitioning from polo fields to college campuses and boardrooms. Its enduring adaptability is demonstrated by distinct reinventions across the decades; the ability to evolve has ensured the polo shirt's lasting relevance and cultural significance.As the official sports brand of the USPA, founded in 1890 and one of the oldest sports governing bodies in the United States, U.S. Polo Assn. occupies an authentic place in the history of the polo shirt."The polo shirt's DNA is deeply rooted in the inspirational sport that inspired it," said J. Michael Prince, President and CEO of USPA Global, the company that manages and markets the multi-billion-dollar, global U.S. Polo Assn. brand. "With An Icon Born from the Game, we're honoring a legacy that began on the field and continues to shape how polo players, sports fans, and consumers all over the world live, move, and express themselves today, and for future generations."An Icon Born from the Game reinforces that legacy by connecting the polo shirt's origins in the sport, while celebrating its place in modern culture."The polo shirt was designed for the game with a real purpose on the field, but it's also what I wear off the field to go out to dinner or hang out with friends and family," said Nico Escobar, U.S. Polo Assn. Global Brand Ambassador, 6-goal American professional polo player. "I love that U.S. Polo Assn. understands both the performance aspect and how the polo shirt fits into everyday life.""U.S. Polo Assn.'s authentic connection to the sport and the way it supports the game of polo around the world is why I wear it - both on the field and off," adds Escobar.Global Launch: An Icon Born from the GameLaunching globally across 190 countries in Spring 2026, An Icon Born from the Game will come to life through a coordinated, multi‑channel presence designed to make the U.S. Polo Assn. polo shirt unmistakably visible wherever consumers engage with the sport-inspired brand. In stores, dedicated polo shirt focus areas, including the brand's iconic polo walls, window displays, and visual merchandising moments, will highlight the full range of styles through bold color stories, clear categorization, and campaign signage anchored by the slogan.Across outdoor and print advertising, hero imagery shot on location brings the polo shirt back to the field, reinforcing its authentic connection to the sport, while digital and social media activations extend the story through short‑form content and global storytelling. Together, these touchpoints create a consistent, immersive expression of the polo shirt as a true icon rooted in sport but relevant to everyday life.Further, An Icon Born from the Game is launching around two of the sport's most important events in the United States - the prestigious USPA Gold Cup® and one of the most competitive tournaments in the world, the U.S. Open Polo Championship®, which concludes with the Championship Final on April 26."An Icon Born from the Game is about owning our truth and telling it boldly on a global scale," said Stefanie Coroalles, Vice President, Global Brand Marketing. "The Global Polo Shirt Campaign brings together heritage, product, and self-expression, showing how the polo shirt moves effortlessly from sport to everyday life.""This launch is a proud moment for us, one that brings our heritage to life in a way that feels modern, visible, and unmistakably U.S. Polo Assn.," adds Coroalles.Product Pillars: Play It Your Way"Every U.S. Polo Assn. polo shirt is designed with intention by balancing style, comfort, function, and authentic sport details," said Brian Kaminer, Senior Vice President, Brand and Product Development. "From heritage-inspired construction to modern performance fabrics, our U.S. Polo Assn. collections reflect how the polo shirt continues to evolve while staying true to its sports roots."The global polo shirt campaign showcases the versatility of the icon through five distinct expressions that give the consumer the opportunity to "Play It Your Way" when styling with the polo shirt.Play It Sporty is the polo shirt that carries the legacy of U.S. Polo Assn. in every stitch. Featuring authentic detailing, iconic branding, and sport-inspired elements, this timeless silhouette connects directly to the game that started it all. Official crests, classic cuts, and traditional design details celebrate the sport of polo's history and the brand's deep-rooted heritage.Play It Classic is the polo shirt for the moments that make up everyday life. Clean, comfortable, and easy to style, it's the go-to option when you want something that always works. Designed to be worn again and again, it fits seamlessly into any routine, whether casual, relaxed, or slightly dressed up.Play It in Motion with the performance polo shirt engineered for action. Advanced technical fabrics deliver moisture-wicking comfort, breathability, and stretch that moves with you throughout the day. Designed for polo players on the field or in life in motion, it balances durability and function with a sharp, modern look.Play It Bold is the fashion polo shirt built for self-expression. Defined by confidence and style, this version brings personality and freedom to a familiar icon. Worn casually or styled with intention, it shows how versatile the polo shirt can be when it's shaped by confidence and worn on an individual's own terms.Play It Elevated is the premium polo shirt made for moments that call for refinement. Crafted with elevated materials and thoughtful detailing, it offers a polished look without feeling formal. Clean lines and a thoughtful fit create a composed yet confident style that balances ease with sophistication.U.S. Polo Assn.'s seasonal polo shirts are offered across men's, women's, and kids' collections in an expansive range of fabrics, finishes, and colors - from classic neutrals to vibrant hues. Updated designs feature textured ribs, subtle patterns, and elevated construction details, finished with the brand's signature Double Horsemen logo - a mark of authenticity and a symbol of the sport.U.S. Polo Assn. continues to incorporate products aligned with its global sustainability program, USPA Life, reflecting the brand's commitment to responsible sourcing and long-term environmental initiatives. The USPA Life Polo Shirt, arriving in stores Spring 2027, builds on U.S. Polo Assn.'s most iconic style, designed with thoughtfully chosen, preferred materials that reflect the brand's commitment to improving the global footprint of this iconic staple. From 100% preferred cotton fabric to the finishing details like buttons and thread, each element has been selected to reduce impact while preserving the classic look, comfort, and quality customers expect from a U.S. Polo Assn. polo shirt.U.S. Polo Assn. apparel and accessories are available in U.S. Polo Assn. stores and online at uspoloassnglobal.com.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sports content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +954.673.1331 - E-mail: skovalsky@uspagl.comKaela Drake - Senior PR and Comms SpecialistPhone +561.530.5300 - E-mail: kdrake@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛罗里达州西棕榈滩, 2026年3月26日 - (亚太商讯 via SeaPRwire.com) - 作为1890年成立的美国马球协会（USPA）官方运动品牌，U.S. Polo Assn. 今日宣布启动其全球马球衫宣传活动——“源自赛场的经典”。此次全球宣传活动旨在向标志性的马球衫致敬，既彰显其纯正的运动血统，也展现其演变为全球最具持久魅力的时尚单品之一的过程。U.S. Polo Assn. 全球品牌大使、6级美国职业马球运动员尼科·埃斯科巴（Nico Escobar）身着马球白装及经典海军蓝 U.S. Polo Assn. 马球衫，骑着爱驹观赛，演绎“源自赛场的经典”U.S. Polo Assn. 模特身着马球衫，亮相于南卡罗来纳州查尔斯顿举办的2026春夏全球系列大片拍摄现场以U.S. Polo Assn.模特为主角的“Polo衫：源自赛场的经典”宣传大片Polo衫的起源可追溯至马球赛场，它由运动、竞技以及其命名所源自的马球精神所塑造。自诞生之初，Polo衫便以功能性为设计核心，专为追求赛场表现的马球运动员而打造。如今，U.S. Polo Assn. 致敬这款永恒经典，它不仅是一件时尚单品，更是源自体育运动、经由世界各地数代运动员与消费者传承至今的标志性象征。Polo衫是拥有逾百年历史的最具标志性的经典单品之一，以其运动与时尚的独特融合而著称。最初采用透气的平纹针织面料、柔软的领口和轻盈的结构设计，以满足竞技运动的需求，如今它已演变为一款永恒的经典单品，既适合展现休闲优雅，也适合日常休闲穿着。Polo衫的起源可追溯至马球运动员，其诞生源于运动的实际需求。马球运动员曾对长袖棉质衬衫进行改良，以更好地应对比赛中的高温、动作和风力。这些功能性、运动驱动的改良，正是后来Polo衫的雏形。20世纪初，随着马球运动日益普及，马球运动员们将这些功能性元素正式确立下来，从而强化了Polo衫与这项运动及其功能性设计的紧密联系。多年来，Polo衫已成为全球休闲运动装的基石，象征着学院风、奢华休闲文化以及当代运动休闲风，从马球场到大学校园再到董事会会议室，其风格转换自如。数十年来，Polo衫历经多次独特革新，彰显了其持久的适应性；这种不断演变的能力，确保了Polo衫经久不衰的时尚地位和文化意义。作为成立于1890年、美国历史最悠久的体育管理机构之一——美国马球协会（USPA）的官方运动品牌，U.S. Polo Assn.在马球衫的历史长河中占据着无可替代的地位。“马球衫的基因深深植根于孕育它的这项鼓舞人心的运动之中，”USPA Global总裁兼首席执行官J. Michael Prince表示。该公司负责管理和推广价值数十亿美元的全球性品牌U.S. Polo Assn.。“通过‘源自赛场的传奇’这一主题，我们致敬了始于赛场、并持续塑造着当今乃至未来几代马球运动员、体育迷和消费者生活方式、行动方式及自我表达方式的传承。”“源自赛场的传奇”通过将马球衫与马球运动的起源相联结，同时颂扬其在现代文化中的地位，从而进一步强化了这一传承。“马球衫最初是为比赛设计的，在赛场上有着切实的用途，但它也是我场下外出就餐或与亲朋好友聚会时的日常穿搭，”U.S. Polo Assn. 全球品牌大使、6级美国职业马球运动员尼科·埃斯科巴说道，“我很欣赏U.S. Polo Assn. 既注重性能表现，又懂得如何将马球衫融入日常生活。”“U.S. Polo Assn. 与马球运动的深厚渊源，以及它对全球马球运动的支持，正是我无论在赛场内还是赛场外都选择穿着它的原因，”埃斯科巴补充道。全球发布：源自赛场的经典“源自赛场的经典”系列将于2026年春季在全球190个国家同步上市。通过精心策划的多渠道整合营销，该系列将生动呈现，确保无论消费者在何处接触这个运动灵感品牌，都能清晰辨识出U.S. Polo Assn.的马球衫。在实体店中，专门的马球衫展示区——包括品牌标志性的马球墙、橱窗陈列及视觉营销亮点——将通过大胆的色彩搭配、清晰的分类以及以口号为核心的宣传标识，全面展示全系列款式。在户外及平面广告中，实地拍摄的主视觉画面将马球衫带回赛场，强化了其与这项运动的真实联系；而数字及社交媒体营销活动则通过短视频内容和全球化叙事延伸这一故事。这些触点共同构成了一个连贯且沉浸式的表达，展现了马球衫作为真正标志性单品的特质——它植根于体育运动，却又与日常生活息息相关。此外，“源自赛场的标志”营销活动将围绕美国马球界两大重要赛事展开——享有盛誉的USPA金杯赛®以及全球竞争最激烈的赛事之一——美国马球公开赛®，该赛事将于4月26日迎来冠军决赛。“‘源自赛场的经典’旨在彰显我们的真实本色，并以大胆姿态向全球讲述这一故事，”全球品牌营销副总裁斯蒂芬妮·科罗亚莱斯（Stefanie Coroalles）表示。“此次全球Polo衫宣传活动将品牌传承、产品与自我表达融为一体，展现了Polo衫如何从运动场无缝融入日常生活。”“此次发布令我们倍感自豪，它以一种现代、醒目且不折不扣的U.S. Polo Assn.风格，让我们的品牌传承焕发新生，”科罗亚莱斯补充道。产品核心理念：随心演绎“每一件 U.S. Polo Assn. polo 衫都经过精心设计，在风格、舒适度、功能性以及正宗的运动细节之间取得了完美平衡，”品牌与产品开发高级副总裁布莱恩·卡米纳（Brian Kaminer）表示。“从受传统启发的剪裁到现代功能性面料，我们的 U.S. Polo Assn. 系列展现了 polo 衫在忠于其运动本源的同时，如何不断演变。”此次全球马球衫宣传活动通过五种截然不同的风格诠释，展现了这一经典单品的百搭特性，让消费者在搭配马球衫时能够“随心而动”。“运动风”系列马球衫的每一针一线都承载着U.S. Polo Assn.的传承。凭借正宗的细节处理、标志性的品牌标识以及运动灵感元素，这款永恒的剪裁设计直接呼应了品牌起源的马球运动。官方徽章、经典剪裁与传统设计细节，共同致敬马球运动的历史与品牌深厚的传承。“经典风范”系列专为日常生活的点滴时刻而生。简约、舒适且易于搭配，是您追求百搭之选时的首选。这款设计旨在经久耐穿，无论休闲、惬意还是稍显正式的场合，都能完美融入您的日常穿搭。Play It in Motion 系列专为动态活动打造的高性能POLO衫。采用先进技术面料，具备吸湿排汗、透气舒适及弹性伸展特性，全天候随您自由活动。无论是在赛场上还是生活中，这款专为POLO球手设计的POLO衫，在兼顾耐用性与功能性的同时，更呈现出利落现代的造型。Play It Bold 系列是专为自我表达而生的时尚POLO衫。这款POLO衫以自信与风格为特质，为经典单品注入个性与自由。无论是随性穿着还是精心搭配，它都展现了当Polo衫由自信塑造、并按个人方式穿出时，其多变的魅力。Play It Elevated是专为需要精致时刻打造的顶级Polo衫。采用高级面料与精心细节，呈现出精致外观却不显拘谨。简洁的线条与考究的剪裁，营造出从容而自信的风格，在舒适与优雅之间取得完美平衡。U.S. Polo Assn.本季的Polo衫涵盖男装、女装及童装系列，面料、工艺与色彩选择丰富多样——从经典中性色到鲜艳亮色应有尽有。新款设计融入了纹理罗纹、低调图案及精湛的工艺细节，并饰有品牌标志性的双骑士徽标——既是正品的印记，也是这项运动的象征。U.S. Polo Assn. 持续推出符合其全球可持续发展计划“USPA Life”的产品，彰显了品牌对负责任采购及长期环保举措的承诺。将于2027年春季登陆门店的“USPA Life”Polo衫，以U.S. Polo Assn.最具标志性的款式为基础，采用精心挑选的优质面料，体现了品牌致力于改善这款经典单品对全球环境影响的承诺。从100%优质棉面料到纽扣、缝线等细节处理，每个元素的选用都旨在减少环境影响，同时保留顾客对U.S. Polo Assn.马球衫所期待的经典外观、舒适度与品质。U.S. Polo Assn.的服装及配饰可在U.S. Polo Assn.门店及官网uspoloassnglobal.com购买。关于 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 是美国马球协会（USPA）的官方运动品牌。USPA 成立于 1890 年，是美国规模最大的马球俱乐部和马球运动员协会。U.S. Polo Assn. 业务规模达数十亿美元，通过全球1,200多家零售店及数千个其他销售网点进行分销，为全球190多个国家的男女及儿童提供服装、配饰和鞋履。该品牌赞助了全球各大马球赛事，包括每年在棕榈滩的NPC举行的美国公开马球锦标赛®——这是美国最顶级的马球锦标赛。通过与美国ESPN、欧洲TNT和Eurosport以及印度Star Sports达成的历史性合作，由U.S. Polo Assn.赞助的数项世界顶级马球锦标赛现已实现电视转播，使全球数百万体育迷首次得以欣赏这项激动人心的运动。根据《License Global》的报道，U.S. Polo Assn. 一直与 NFL、PGA 巡回赛及一级方程式赛车并列为全球顶尖的运动授权商之一。此外，这个以运动为灵感的品牌更因全球业务成长及运动内容而获得国际奖项肯定。凭借其作为全球品牌的巨大成功，U.S. Polo Assn. 曾获《福布斯》、《财富》、《现代零售》及《GQ》等媒体报道，并登上雅虎财经与彭博社等全球众多知名媒体平台。欲了解更多资讯，请造访 uspoloassnglobal.com 并追踪 @uspoloassn。USPA Global 是美国马球协会（USPA）的子公司，负责管理市值数十亿美元的运动品牌 U.S. Polo Assn.。USPA Global 同时管理其子公司 Global Polo，该公司是全球马球运动内容的领导者。欲了解更多资讯，请造访 globalpolo.com 或 YouTube 上的 Global Polo 频道。如需更多资讯，请联系：Stacey Kovalsky - 全球公关与传播副总裁电话 +954.673.1331 - 电子邮件：skovalsky@uspagl.com Kaela Drake - 高级公关与传播专员电话 +561.530.5300 - 电子邮件：kdrake@uspagl.com 消息来源：U.S. Polo Assn. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com